ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ascendis Pharma (ASND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA approval for Yuviwel, bullish technical indicators, and consistent analyst optimism with raised price targets. Despite minor short-term price declines and hedge fund selling, the long-term growth potential outweighs these negatives.
The technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 57.323, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key support is at 223.142, with resistance at 245.329. The stock is trading near the pivot point (234.236), suggesting potential upward movement.
FDA approval for Yuviwel, the first once-weekly treatment for children with achondroplasia, with commercialization expected in early Q2
Analyst upgrades with raised price targets (e.g., Stifel to $332, RBC Capital to $275).
Strong growth potential for Yorvipath and TransCon CNP, with management targeting EUR 5B in annual revenues by 2030.
Hedge funds are selling, with a 565.41% increase in selling activity last quarter.
Insider trading is neutral, with no significant buying activity.
Minor short-term price decline (-1.67% regular market change).
In Q4 2025, revenue remained flat YoY at $247.5M, net income improved to -$33.56M, and EPS increased to -$0.55. Gross margin is strong at 90.47%, reflecting efficient operations despite negative earnings.
Analysts are highly optimistic, with multiple firms raising price targets and maintaining Buy or Outperform ratings. Stifel raised its target to $332, RBC Capital to $275, and Wells Fargo to $330. Analysts highlight the FDA approval of Yuviwel and the growth potential of Yorvipath as key drivers for the stock.
